Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product
UPPSALA, Sweden, Aug. 29, 2023 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the amorphOX® drug delivery platform.
Related news for (ORXOY)
- Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
- Orexo AB´s sustainability work ranked among top 5% by EcoVadis
- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds